CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells
- PMID: 20463596
- DOI: 10.1097/CJI.0b013e3181d75cef
CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells
Abstract
The requirement for CD4 T cells in priming and maintaining cytotoxic T-lymphocyte responses presents a long-standing paradox in cellular immunology. In this study, we used sequential coadministration of a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii-peptide region is replaced with CD4 T-helper epitope, PADRE [Pan human leukocyte antigen-DR reactive epitope (Ii-PADRE)] or Bcl-xL with a DNA vaccine encoding Sig/E7/LAMP-1 to verify the role of CD4 T cells for the generation of effectors and memory E7-specific CD8 T-cell immune responses. Sequential vaccination, with Ii-PADRE+Sig/E7/LAMP-1 priming followed by Bcl-xL+Sig/E7/LAMP-1 boosting led to generation of E7-specific CD8 T cells, and was nearly equivalent in effect to coadministration with Ii-PADRE+Sig/E7/LAMP-1 or Bcl-xL+Sig/E7/LAMP-1 at both prime and boost. The mice vaccinated with the Ii-PADRE+Sig/E7/LAMP-1 prime-Bcl-xL+Sig/E7/LAMP-1 boost regimen exhibited better long-term E7-specific immune responses and tumor prevention effects in vivo than the mice vaccinated with the reverse sequential coadministration. After CD4 T-cell depletion, mice primed with Ii-PADRE+Sig/E7/LAMP-1 generated low numbers of E7-specific CD8 T cells and suppressed long-term memory CD8 T-cell response regardless of the sequence or combination of DNA vaccines administered. Mice primed with Bcl-xL+Sig/E7/LAMP-1 only suppressed long-term memory CD8 T-cell response after depletion of CD4 T cells before priming. Our findings suggest that activated CD4 T cells at prime phase are important to generate the antigen-specific CD8 T-cell immune responses and CD4 T cells, which are naive or activated, play a role to maintain the long-term memory responses.
Similar articles
-
DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.Hum Gene Ther. 2005 Jan;16(1):26-34. doi: 10.1089/hum.2005.16.26. Hum Gene Ther. 2005. PMID: 15703486
-
Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.Gene Ther. 2001 Jan;8(2):128-38. doi: 10.1038/sj.gt.3301370. Gene Ther. 2001. PMID: 11313782
-
Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543. Eur J Immunol. 2009. PMID: 19637230
-
CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.Vaccine. 2012 Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3. Vaccine. 2012. PMID: 22386748 Review.
-
IL-1β strikingly enhances antigen-driven CD4 and CD8 T-cell responses.Cold Spring Harb Symp Quant Biol. 2013;78:117-24. doi: 10.1101/sqb.2013.78.021246. Epub 2013 Oct 3. Cold Spring Harb Symp Quant Biol. 2013. PMID: 24092469 Review.
Cited by
-
Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.Immunol Cell Biol. 2015 Jan;93(1):86-98. doi: 10.1038/icb.2014.74. Epub 2014 Sep 16. Immunol Cell Biol. 2015. PMID: 25223833
-
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.Hum Vaccin Immunother. 2013 Oct;9(10):2165-77. doi: 10.4161/hv.24941. Epub 2013 Jun 4. Hum Vaccin Immunother. 2013. PMID: 23899517 Free PMC article. Clinical Trial.
-
Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity.PLoS One. 2015 May 11;10(5):e0126075. doi: 10.1371/journal.pone.0126075. eCollection 2015. PLoS One. 2015. PMID: 25961716 Free PMC article.
-
Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.J Cancer Res Clin Oncol. 2013 May;139(5):861-70. doi: 10.1007/s00432-013-1394-4. Epub 2013 Feb 15. J Cancer Res Clin Oncol. 2013. PMID: 23411688 Free PMC article.
-
Chemokine-enhanced DNA vaccination in cancer immunotherapy.Oncoimmunology. 2013 Oct 1;2(10):e26092. doi: 10.4161/onci.26092. Epub 2013 Sep 12. Oncoimmunology. 2013. PMID: 24251079 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous